All Research
Page 5 of 10 · 219 reports
The leading U.S. pickup and SUV maker, holding 17.2% U.S. market share in 2025 with a net-cash automotive balance sheet; but its China joint ventures posted a 300 million equity loss in 2025, Cruise is undergoing a strategic reset, and gross tariff costs of 2.5 to 3.5 billion keep eroding profit. The ideal buy zone is 55 to 70 dollars, while the current 78.79 dollars leaves an insufficient margin of safety. Rating Watch: cheap on valuation, but not yet cheap enough to offset weak industry quality and long-run uncertainty.
The largest U.S. downstream plus midstream energy platform, with 3.0 mbpd of refining capacity, the MPLX midstream business, and 7,882 branded retail outlets. Capital-allocation discipline is strong (cumulative buybacks of $24 billion over 2023-2025 shrank the share count by 27%), but at $254.65 the stock already sits at the top of its optimistic valuation band, leaving little margin of safety. Rating Watch: an excellent operator running a cyclical asset portfolio, but priced close to the best-case outcome rather than offered at a discount.
One of the three largest independent refiners in the United States, with strong operations and a sound balance sheet, yet fundamentally a spread business with no real pricing power. At the current price of $246.96, the stock already sits near the floor of the optimistic scenario and offers no margin of safety. Rating Watch: an excellent operator in a poor industry, fairly priced for a continued upcycle rather than for safety.
A top-tier global alternative-asset platform (alternative asset management + Global Atlantic insurance + strategic holdings). At 94.04 dollars the stock is roughly fair on neutral assumptions, but a governance discount, insurance risk, and a not-cheap ~22x conservative owner earnings leave little margin of safety. Rating Watch: a high-quality but complex compounder worth waiting on, with an ideal buy zone of 70-85 dollars.
A global low-cost, cross-border, multi-asset automated brokerage platform; 2025 net revenue of 6.205 billion dollars at a 76.9% pre-tax margin. At roughly 75 dollars per share the stock sits at the upper end of fair value, with no meaningful margin of safety. Rating Watch: an excellent business trading at a full price rather than a clearly undervalued opportunity.
The tirzepatide platform has put Lilly at the top of the metabolic disease arena, but the $732 share price has already paid in advance for the next-generation pipeline and capacity expansion; a neutral DCF intrinsic value of only $560-680 leaves an insufficient margin of safety, making it better to wait for a pullback. Rating Watch: a great business whose current price gives long-term owners too little room for error.
The world's flagship gold resource company, with 2025 revenue of $22.67 billion and $7.3 billion in free cash flow amplified by rising gold prices; yet at its core it remains a capital-heavy, deeply cyclical mining company with little pricing power, and today's price already discounts both peak gold prices and a successful-integration narrative. Ideal entry $35-50. Rating Watch: a top-tier gold resource base whose current price prices in the good news, better tracked than bought.
An institutionalized intangible-asset earnings machine, with 2025 free cash flow of 5.135 billion dollars and capex at just 1.3% of revenue. At the current price of 417.60 dollars, roughly 26.4x trailing PE, it sits in the middle of its fair-value band, leaving an inadequate margin of safety. Rating Watch: a superb compounder whose quality is already priced in, so buying here means paying for long-term quality rather than buying an obvious bargain.
The leading enterprise workflow operating-system platform (post-split share price $102.25), with strong subscription stickiness and high cash-flow quality, yet on a conservative Owner Earnings basis that treats stock-based compensation as a real cost, the roughly 41x multiple still looks tight; ideal buy range $70-85. Rating Watch: an excellent business, but at today's price you are buying the expectation of continued excellence rather than an obviously undervalued asset.
A scarce Hong Kong-listed name on the digital-twin and physical-AI theme, with 2025 revenue of RMB 348 million and a gross margin that fell from 51.1% to 30.0%; at roughly 100x P/S, the price already discounts the optimistic scenario. 51Aes remains the engine of the income statement while the 51Sim growth leg has yet to monetize, putting a fair buy range at HK$35 to HK$50. Rating Watch: the technology and the theme are both scarce, but the current price has already priced in the bull case and needs 51Sim ramp and margin repair to be confirmed by the financials.
A scarce Hong Kong-listed digital-twin pure play that still lost RMB 186 million in 2025, runs negative operating cash flow, and saw gross margin fall from 51.1% to 30.0%; at the current HK$98.55 the stock trades at more than 100x P/S, which has already bought the most distant success in advance. Owner earnings remain negative and the fair buy band is HK$5–10. Rating Avoid: a good story with weak cash flow priced for a future that has not yet shown up in the financials.
A global spirits leader built on the Jack Daniel's family, high gross margins, and a long dividend record. Net sales fell 5% in FY2025 and another 2% over the first nine months of FY2026, with management still guiding to a low-single-digit decline. At roughly $26 the stock sits in the middle of a $24–30 fair-value range, with an ideal buy zone of $20–23. Rating Watch: a high-quality compounder now priced closer to fair value than to a bargain, leaving little margin of safety.
A global diversified holding-company leader: 176 billion in insurance float, 397.4 billion in cash and short-term Treasuries, and 67 billion in net income. The capital-allocation record is excellent, but the Abel era is still unproven. At the current 486.38 dollars, with an ideal entry of 350 to 410 dollars, the margin of safety is not obvious. Rating Hold: a high-quality compounder priced fairly rather than cheaply.
A global alternative asset management platform with $1.304 trillion in AUM and $539.7 billion in perpetual capital. At $118.51, the stock trades at roughly 19.5x economic-interest P/DE, with its quality premium already fully priced in. Rating Watch: a top-tier franchise worth owning, but only at a price that offers a real margin of safety, so wait for a better entry point as fundraising, exits, or valuation multiples reset.
A gateway-city Class A office REIT. At $60.29, the stock trades at 8.87x Price/FFO, 1.86x PB, and a 4.64% dividend yield. Asset quality is better than the industry average, but a demand re-rating plus heavy capex still pressure free cash flow. Rating Watch: a high-quality asset base in a headwind industry, priced fairly rather than cheaply; ideal buy price $40–48.
A packaged-food company with mid-tier brands and a mid-tier moat. At $13.56, the stock trades at roughly 5x FY2025 P/FCF, and it is cheap for good reasons: high leverage, volume pressure, and a new CEO, John Brase, taking over in June. Rating Watch: a cheap cash-flow asset rather than a high-quality compounder, with an ideal buy range of $11 to $13.
Market cap of 1.51 trillion dollars and a trailing P/E near 391x mean the current 426 dollar price already pays for a long-dated Physical AI option; the core auto business is slowing while energy storage gross margin has climbed to 39.5% to become a second profit center. Rating Cautious Neutral: a high-beta transition story that is richly priced today, while a high-convexity upside option on autonomy and robotics stays alive.
A three-part asset: a best-in-class commercial space business, the Starlink cash engine, and an xAI platform option. 2025 revenue reached $18.67 billion, but AI lost $6.36 billion and Q1 capex hit $10.1 billion; the $1.75 trillion IPO target prices the future far too early, so we watch the $0.95–1.20 trillion range. Rating Watch: a top-tier asset saddled with excessive expectations and extremely weak governance.
A highly efficient global value e-commerce platform: a 2025 operating margin of 21.6% and roughly 9.6x PE are not expensive. But Temu has lost its small-parcel policy windfall, while domestic price wars and instant retail squeeze the profit center; with a fair buy range of $70–82 and insufficient margin of safety, Rating Watch: high cash flow and low valuation coexist, but Temu's policy regime and profit center await repricing.
A leader in agricultural supply-chain management, ADM posted $80.3 billion in 2025 revenue but only $1.078 billion in net income attributable to shareholders, on a 34.6x trailing P/E. The cash-flow improvement came largely from working-capital release, while the 2024 internal-control deficiency and the persistent gap between Nutrition's long-term promises and its returns weigh on management credibility. Rating Watch: today's price is a prepayment for a cyclical recovery, not a discounted entry into a steady cash machine.
A high-quality, subscription-heavy cloud security platform: FY2026 Q2 subscription mix at 84%, steady ARR growth, and 3.5 billion in net cash. The catch is price: forward EV/S near 8.2x, P/FCF near 33x, GAAP still in the red, and heavy stock-based compensation that drags down true owner earnings, leaving today's roughly 180 dollars sitting at the low end of an optimistic scenario. Rating Watch: an excellent business at a price that offers conservative investors little margin of safety.
FY2026 subscription revenue is 92% of the total, subscription backlog stands at 28.1 billion dollars, and gross retention is 97%, so business quality is solid. But how you treat stock-based compensation directly determines real shareholder returns, buyback timing has been off (average price 226.62 dollars versus 128.14 today), and the stock looks cheap on P/FCF yet not cheap on a GAAP basis, leaving a thin margin of safety. Rating Watch: a high-quality operator that has not yet earned an unarguable margin of safety.
A combination of streaming, studios, and linear television; 2025 FCF of 3.1 billion gives a 4.6% FCF yield, roughly even with the 4.57% 10-year Treasury. The PSKY merger at $31 per share in cash has shareholder approval, and today's 27.03 already carries an event premium; on standalone operating value the ideal buy range is $12-17, leaving the current price neither cheap nor clean. Rating Watch: a strong-asset company mid-transformation whose price already prices in the deal, with too little standalone margin of safety for a conservative long-term owner.
The global EDA leader, now in the middle of integrating Ansys. FY25 revenue reached 7.054 billion with 77% gross margin and R&D running at 35% of revenue. At 80.9x PE, the current price already bakes in both a successful integration and a failure to commoditize, leaving an ideal buy range of 300 to 380 dollars. Rating Watch: a high-quality business priced with no margin of safety.